Nitsche, Mirko

[["dc.bibliographiccitation.firstpage","1113"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Journal of Cancer Research and Clinical Oncology"],["dc.bibliographiccitation.lastpage","1120"],["dc.bibliographiccitation.volume","138"],["dc.contributor.author","Nitsche, Mirko"],["dc.contributor.author","Christiansen, Hans"],["dc.contributor.author","Lederer, Katinka"],["dc.contributor.author","Griesinger, Frank"],["dc.contributor.author","Schmidberger, Heinz"],["dc.contributor.author","Pradier, Olivier"],["dc.date.accessioned","2018-11-07T09:08:54Z"],["dc.date.available","2018-11-07T09:08:54Z"],["dc.date.issued","2012"],["dc.description.abstract","Fludarabine is an adenine nucleoside analogue that has significant activity in hematological malignancies and has shown promising activity in combination with radiation in preclinical solid tumor models. We designed a phase I trial exploring concurrent fludarabine and radiotherapy in patients with advanced non-small cell lung cancer (NSCLC) to determine the maximum tolerated dose (MTD) of fludarabine given with concurrent irradiation. Thirteen patients with stage IIIB NSCLC received thoracic irradiation of 60 Gy. Fludarabine was administered during the 5th and 6th week of radiotherapy. Doses started at 10 mg/m(2) per day and increased by steps of 3 mg/m(2) per day. At a daily dose of 16 mg/m(2), one out of six patients developed a grade 4 leukopenia, and one a grad 3 pneumonitis. Further grade III toxicity was not observed. The dose of 13 mg/m(2) was identified as the MTD. All patients developed a fludarabine dose-dependent lymphocytopenia. Fludarabine can be safely administered concurrently with radiation at a daily dose of 13 mg/m(2) during the final 2 weeks of radiotherapy. Further prospective clinical studies are required to establish the potential role of concurrent fludarabine and radiotherapy in the treatment of locally advanced inoperable NSCLC."],["dc.identifier.doi","10.1007/s00432-012-1185-3"],["dc.identifier.isi","000305196200004"],["dc.identifier.pmid","22402597"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/8813"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26140"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0171-5216"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Fludarabine combined with radiotherapy in patients with locally advanced NSCLC lung carcinoma: a phase I study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","31"],["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.issue","31"],["dc.bibliographiccitation.journal","Radiation Oncology"],["dc.bibliographiccitation.lastpage","10"],["dc.bibliographiccitation.volume","2"],["dc.contributor.author","Hermann, Robert Michael"],["dc.contributor.author","Schwarten, Dag"],["dc.contributor.author","Fister, Stefanie"],["dc.contributor.author","Grundker, Carsten"],["dc.contributor.author","Rave-Frank, Margret"],["dc.contributor.author","Nitsche, Mirko"],["dc.contributor.author","Hille, Andrea"],["dc.contributor.author","Thelen, Paul"],["dc.contributor.author","Schmidberger, Heinz"],["dc.contributor.author","Christiansen, Hans"],["dc.date.accessioned","2018-11-07T10:59:33Z"],["dc.date.available","2018-11-07T10:59:33Z"],["dc.date.issued","2007"],["dc.description.abstract","Background: Oncological results of radiotherapy for locally advanced prostate cancer (PC) are significantly improved by simultaneous application of LHRH analoga (e. g. goserelin). As 85% of PC express LHRH receptors, we investigated the interaction of goserelin incubation with radiotherapy under androgen-deprived conditions in vitro. Methods: LNCaP and PC-3 cells were stained for LHRH receptors. Downstream the LHRH receptor, changes in protein expression of c-fos, phosphorylated p38 and phosphorylated ERK1/2 were analyzed by means of Western blotting after incubation with goserelin and irradiation with 4 Gy. Both cell lines were incubated with different concentrations of goserelin in hormone-free medium. 12 h later cells were irradiated (0 - 4 Gy) and after 12 h goserelin was withdrawn. Endpoints were clonogenic survival and cell viability (12 h, 36 h and 60 h after irradiation). Results: Both tested cell lines expressed LHRH-receptors. Changes in protein expression demonstrated the functional activity of goserelin in the tested cell lines. Neither in LNCaP nor in PC-3 any significant effects of additional goserelin incubation on clonogenic survival or cell viability for all tested concentrations in comparison to radiation alone were seen. Conclusion: The clinically observed increase in tumor control after combination of goserelin with radiotherapy in PC cannot be attributed to an increase in radiosensitivity of PC cells by goserelin in vitro."],["dc.description.sponsorship","Deutsche Krebshilfe [106240]"],["dc.format.mimetype","application/pdf"],["dc.identifier.doi","10.1186/1748-717X-2-31"],["dc.identifier.fs","119077"],["dc.identifier.isi","000260343200001"],["dc.identifier.pmid","17718927"],["dc.identifier.ppn","559810636"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/4370"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/50728"],["dc.language.iso","en"],["dc.notes.intern","Migrated from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Biomed Central Ltd"],["dc.relation.issn","1748-717X"],["dc.rights","Goescholar"],["dc.rights.access","openAccess"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","616"],["dc.title","No supra-additive effects of goserelin and radiotherapy on clonogenic survival of prostate carcinoma cells in vitro"],["dc.title.subtitle","Research"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]